Manufacturing Partnerships PH-762 requires scalable formulation and manufacturing; Phio has an active CDMO relationship with Pyramid Labs and can scale production for Phase 1b trials and potential commercialization. There is an opportunity to broaden CDMO partnerships for fill/finish, testing, and supply chain services to support intratumoral delivery therapies across cSCC, melanoma, and Merkel cell carcinoma. Target manufacturing vendors with capabilities in oncology biologics and complex aseptic processes.

Clinical Collaborations PHIO's lead candidate is in early-stage trials for skin cancers; opportunities exist to partner with CROs, academic centers, and oncology networks to run investigator-initiated trials or co-development programs. A broader development alliance could accelerate data generation, expand indications, and create shared risk/reward with potential milestone and royalty structures.

IO Synergy INTASYL's self-delivering siRNA could complement checkpoint inhibitors and other IO assets; potential licensing or collaboration with companies pursuing combination regimens may unlock new indications and faster patient access.

Funding Pathways An ATM offering agreement with H.C. Wainwright signals ongoing capital access to fund pipeline expansion, manufacturing, and clinical activities. This opens avenues for strategic investments, milestone-based licensing deals, or co-development arrangements with pharma partners; participate in investor events to identify potential BD partners.

Strategic Alliances Phio's strong IP position around INTASYL and its Nobel-laureate founder history enhances attractiveness to specialty pharma seeking novel IO modalities. Initiate discussions for licensing or co-development deals with mid-to-large biotech or pharma players focused on immuno-oncology, intratumoral therapies, or combination regimens.